AstraZeneca reports $275m in vaccine sales

Marco Green
April 30, 2021

Just 526 were patients who had received a first jab at least three weeks before, the time required to build protection - a rate of one per cent.

A very small number of mainly frail, elderly Covid-19 patients are being hospitalized and dying even after having a first dose of Pfizer's or AstraZeneca's vaccines, but this does not mean the shots aren't working, United Kingdom researchers said on Friday.

It is the first time that the company has disclosed figures from sales of one of the world's leading vaccines.

A total $43 million were in emerging markets, and $8 million in the rest of the world, it added.

AstraZeneca's chief executive Soriot said it did its best to deliver as many doses as possible to the European Union, and while disappointed not to have delivered more, he was proud of the company's work and was "totally committed" to increasing supply.

AstraZeneca vaccine production had been rapidly assembled following the start of the outbreak in early 2020.

"We are seeing signs that it is reducing transmissions", he added, citing recent United Kingdom data.

The European Commission has launched legal proceedings against the Anglo-Swedish drugmaker, alleging that it did not respect its contract or have a "reliable" plan to ensure timely deliveries of coronavirus shots.

The EU is suing AstraZeneca on the basis of breaches of an advanced purchase agreement, but the firm has dismissed the legal action "without merit" and stated that it will strongly defend itself in court.

The company made the disclosure in an earnings statement showing that net profit doubled in the first quarter to $1.56 billion, compared with $780 million a year earlier.

Prof Semple said the analysis was created to give Sage "a very early signal on whether vaccines were working in the real world", adding: "The absolute numbers of people being admitted to hospital after 21 days of the first dose is tiny".

While a EUA is not needed to export vaccines, the official said, the United States would not export any vaccine that did not meet U.S. safety, efficacy and manufacturing quality standards.

Revenue jumped 15% - or 11% at constant exchange rates - to $7.32 billion in the reporting period.

The firm cautioned however that the Covid pandemic had a "negative impact" on both the diagnosis and treatment of other conditions aside from Covid.

The company has said it plans to ship a total of 100 million doses to the bloc by the end of June, instead of 300 million foreseen in the contract.

Other reports by Click Lancashire

Discuss This Article